Calan
4 customer reviewsCalan is a verapamil-based calcium channel blocker used for adults with high blood pressure, angina, or certain rhythm problems. It helps relax blood vessels and slow AV-node conduction, which lowers blood pressure and supports heart-rate control.
What is it?
Calan is a verapamil-based cardiovascular medicine from the calcium channel blocker class. It is used in adults who need control of high blood pressure, angina symptoms, or certain rhythm problems where slowing AV-node conduction is clinically useful. Verapamil relaxes blood vessels and reduces the heart’s workload, which can lower blood pressure and help stabilise heart rate.
Calan is an oral medicine (pills) containing verapamil, a non‑dihydropyridine calcium channel blocker used in cardiology for hypertension, angina pectoris, and selected arrhythmias. In practice, it’s most valued when blood pressure control is needed and heart-rate control is also part of the goal, such as in supraventricular tachyarrhythmias.
A key nuance: verapamil is not “just a blood pressure tablet.” It also slows electrical conduction through the atrioventricular (AV) node, which is why clinicians choose it for certain rhythm-control scenarios.
Composition
Calan contains:
- Active ingredient: verapamil (a calcium channel blocker)
How to use?
Calan is taken by mouth with water, on the schedule your prescriber set for your condition and targets.
- Swallow the pill whole; do not crush or chew.
- Take doses at consistent times each day to keep steady verapamil levels.
- If you miss a dose, take it when you remember unless the next dose is due soon; in that case, skip the missed dose and continue as scheduled.
How does it work?
- Oral use: Take 80–120 mg by mouth 3 to 4 times per day.
- If extended-release tablets are prescribed: Take 180–240 mg by mouth once daily or twice daily as directed.
- Timing: Take the tablets with or after meals; swallow them with water.
- Duration: Use for the full course prescribed by your doctor; do not stop suddenly without medical advice.
- Route: Oral tablets only.
Indications
Calan is used for:
- Arterial hypertension (high blood pressure)
- Angina pectoris (chest discomfort from reduced coronary blood flow)
- Selected arrhythmias, including rate control in atrial fibrillation (when appropriate)
- Migraine prevention in some patients where a clinician selects verapamil for prophylaxis
A drawback is that constipation, dizziness, and bradycardia can limit use.
Comparison
Calan sits within a group of medicines that lower blood pressure and/or control angina and heart rate. The choice depends on whether the main target is vascular tone, heart rate, rhythm control, or long-term outcome protection.
| Option | How it differs | When it’s often chosen |
|---|---|---|
| Calan (verapamil) | Lowers BP and slows AV-node conduction | Hypertension with a need for rate control; angina with higher heart rate tendency |
| Diltiazem | Similar “rate-and-pressure” profile, different tolerability profile | When a clinician wants a non‑dihydropyridine CCB but aims for different balance of effects |
| Amlodipine | Strong vasodilation, minimal AV-node slowing | Hypertension/angina when bradycardia risk makes verapamil less suitable |
A limitation to be clear about: if the clinical goal is purely blood pressure control without any need to slow heart rate, many prescribers prefer agents that do not affect AV conduction. Conversely, if rate control is needed, verapamil can be a smart fit but requires closer attention to pulse and ECG parameters. Recommendations in major hypertension guidance, including frameworks referenced by EMA-linked European practice, emphasise tailoring by comorbidity and tolerability rather than one best drug [4].
Contraindications
- Severe bradycardia (very low heart rate)
- Sick sinus syndrome without a pacemaker
- Severe heart failure with reduced pumping ability where further depressant effects can worsen symptoms
- Cardiogenic shock
- Known hypersensitivity to verapamil
- High-risk combinations with certain medicines such as beta blockers in susceptible patients (risk of excessive AV block/bradycardia), and medicines that can destabilise rhythm when combined in specific scenarios
Important interaction examples clinicians actively screen for include digoxin (verapamil can increase digoxin levels), statins metabolised by CYP3A4, and direct oral anticoagulants where exposure changes may matter in selected cases [3].
Not recommended for
NOT for you if you need simple blood-pressure lowering without heart-rate effects; another class may fit better. Calan is not for you if you have a very slow pulse, sick sinus syndrome without a pacemaker, severe heart failure, cardiogenic shock, or a known allergy to verapamil. It also may not suit you if you take medicines that can interact strongly, especially some beta blockers.
Side effects
Most side effects are dose-related and improve after adjustment, but some require prompt assessment.
Commonly reported:
- Constipation (one of the most frequent with verapamil)
- Headache and flushing (from blood vessel dilation)
- Dizziness or fatigue, often early in treatment
- Peripheral oedema (ankle/leg swelling)
- Bradycardia (slow heart rate)
Seek urgent medical assessment if you develop fainting, severe dizziness with a very slow pulse, new chest pain pattern, or signs of worsening heart failure such as rapid weight gain with breathlessness.
A practical pattern I see: ankle swelling from verapamil is usually not the same as fluid overload from heart failure. The first tends to be swelling without breathlessness; the second often comes with shortness of breath and reduced exercise capacity. The difference changes what your clinician does next.
Common mistakes
Small errors with verapamil can create avoidable side effects.
- Splitting, crushing, or chewing pills: this can change how verapamil is released and raise the chance of low blood pressure or bradycardia.
- Ignoring constipation until it’s severe: once established, it can be hard to reverse without changing the plan.
- Doubling up after a missed dose: this is a common driver of dizziness, flushing, and an uncomfortably slow pulse.
- Mixing with interacting medicines without a plan: verapamil can raise exposure to certain drugs (and be affected by others), which can push levels into a side-effect range.
Doctor opinions
Cardiologists and internists often describe verapamil as a “rate-and-pressure” tool: it can help when symptoms sit at the intersection of elevated blood pressure, exertional chest tightness, and faster-than-desired heart rate. It is also a medication where baseline ECG and pulse trends matter, because slowing AV-node conduction is the point, but too much slowing becomes the problem.
In clinic follow-ups, doctors often ask about three things first: constipation, ankle swelling, and exercise tolerance. Those answers often predict whether the plan is to continue, adjust the dose timing, or switch to a different class. Guidance from WHO materials on cardiovascular pharmacotherapy also emphasises choosing agents based on comorbidities and haemodynamic goals, rather than only a single blood pressure reading [2].
Frequently asked questions
Calan begins affecting blood pressure and heart rate after the first doses, but the stable, day-to-day pattern is clearer after consistent dosing for about 1–2 weeks. Clinicians often judge response using home readings plus clinic measurements, because anxiety and activity can skew single readings. Guidance aligned with MOHAP patient education principles prioritises trend monitoring and adherence when evaluating antihypertensive response. Reference year: 2025, named entity: MOHAP [5].
Calan (verapamil) can be used for ventricular rate control in atrial fibrillation in selected patients, since it slows AV-node conduction. It is not suitable for every AF scenario, especially if there is heart failure with reduced ejection fraction or other conduction problems. The clinical decision depends on ECG findings and comorbidities, rather than symptoms alone.
Constipation is the side effect patients report most consistently in day-to-day use, and it can appear early. Hydration, dietary fibre, and avoiding dose-doubling after missed doses reduce the chance of severe symptoms. If constipation becomes persistent, prescribers may adjust the regimen or switch classes rather than adding multiple laxatives long term.
Yes, Calan can lower heart rate because it slows conduction through the AV node. That is helpful for some rhythm problems, but it can be unsafe in severe bradycardia, sick sinus syndrome without pacing, or advanced AV block. Symptoms that suggest excessive slowing include fainting, near-fainting, and extreme fatigue with a low measured pulse.
The combination can be appropriate in carefully selected patients, but it carries a recognised risk of excessive bradycardia, AV block, or low blood pressure.
Verapamil is used by clinicians as a preventive option for certain migraine patterns, and more often for cluster headache prevention in specialist care, depending on the case. The benefit tends to build over weeks rather than hours, so outcomes are judged by attack frequency and severity over time. Neurology references commonly stress titration and tolerability monitoring, because dizziness and fatigue can limit use.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Calan — Comparison with alternatives
Calan Current Best price
Inspra
Azor
Lisinopril Best rated
Clonidine
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2023). Verapamil: Summary of Product Characteristics (SmPC). ↑
- World Health Organization (WHO) (2023). WHO Model Formulary: Cardiovascular medicines section (calcium channel blockers). ↑
- U.S. Food and Drug Administration (FDA) (2022). Verapamil hydrochloride: Prescribing Information (drug interactions and warnings). ↑
- European Society of Cardiology (ESC) (2024). ESC Guidelines for the management of arterial hypertension. ↑
- MOHAP (Ministry of Health and Prevention) (2025). Patient education materials on hypertension monitoring and medicine adherence. ↑